<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 321 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page320.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=321">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 321 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 321</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=321"><img src="../thumb/321.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>284 / 2020-04                                                            Anti-Microbials - 18.12
   Drug interactions: Plasma conc.of other compds. that are CYP3A4   Indications: Mono- or combinat.ther.for HIV-1 infect. in adults  decr., carbamazepine poss.incr efavirenz conc., sertraline/ itra-
   substrat.poss.decr., AUC & C max of indinavir /saquinavir/clarithro-  (S4) TABS, 49/20.2.8/0105  conazole/ketoconazole/ posaconazole/ clarithromyc./rifabutin/Ca
   mycin decr., incr. freq. of S/E with ritonavir, rifampicin decr.AUC &   3001080-001: 30, R495,00  chan. block./HMG-CoA reduct. nhibit plasma conc.decr., metha-
   C max ,, methadone plasma lev.decr.result.in opiate withdr. signs in   Dosage: Adults: 1 tab.once dly.on empty stomach. Bedt.dos.may   done plasma lev.decr. result.in opiate withdr. signs in HIV infect.IV
   HIV infect.IV drug users, reduc. plasma conc.with St John’s Wort.  improv.CNS sympt. tolerabil.  drug users, rifampicin decr. efavirenz conc., ethinyl oestrad.conc.incr.
   VIROPON, Novagen [P/S]       Contraindications: Concom.astemizole/ bepridil/ cisapride/ mi-  VOLUTRIP, Aurobindo [P/S]
                                dazolam/pimozide/ triazolam/ergot derivat/ St John’s Wort., con-
   Nevirapine.                  com.voriconazole, mod.-sev.ren.impairm., sev.hepat.impairm., hist.  Dolutegravir sod.equiv to dolutegravir 50 mg, lamivudine 300 mg,
   Indications: In combinat.with at least two addit. antiretrov. agents   of prev. liv.inj./fail.with efavirenz contain.meds., concom. meds/  tenofovir disoproxil fumarate 300 mg
   for HIV-1 infect.            combinat.contain lamivudine, safety & effic.in pts.less than 18 yrs.  Indications: Treatm.of HIV infect.adults ≥ 18 yrs.
   (S4) TABS. A40/20.2.8/0382   not est., pregn. & lactat.    (S4) TABS, 52/20.2.8/0212.210
   710606-001: 200 mg, 60, R289,80  Side effects: Efavirenz: Freq: Hypertriglyceridem., elev.AST/ALT/  3000435-001: 30, R483,00
   (S4) SUSP. A40/20.2.8/0490   GGT, depress., anx., abnorm.dreams, insomn., dizzin., headache,   Dosage: Consult.prod.info.of each therapeut. compon. of regim.bef.
   710604-001: 50 mg/5 ml, 240 ml, R200,37  somnol., cerebell.coordinat./bal.disturb., attent. disturb, drowsin.,   init.treatm., init.ther.by physic. exper.in HIV infect.managem. Adults:
   Dosage: Consult.prod.info.of each therapeut. compon. of regim.  skin reacts.incl.diffuse maculopapul. rash, erythema multiforme,   1 tab. once dly. Rifampicin decr. dolutegravir bld lev.& supplement.
   bef.init.treatm. Do not alter dos. Next dos.to be taken as soon as   photoallerg. dermatit., Stev.-Johns.syndr, prurit., fatig. Less freq:   dos.of dolutegravir poss.reqd.
   poss.if dos.skipp. Pts.exper.rash dur.14 day lead-in per.should not   Hypersens., hypercholesteraem, stupor, confus., impair.conc., ab-  Contraindications: Ren.funct.impairm., pregn.& lactat., women of
   incr.200 mg dos until rash has resolv. Ther.to be interrupt.if mod.  norm.think./vis., agitat., amnes., delir., emotion.lability, euphor.,   child-bear. age not using highly effect.contracept., concom.adefovir
   liv.funct.test abnorm.exper. Re-introduct. poss.based on clinic.  hallucin., psychos., suicide attempt/ideat./ complet., paranoia,   dipivoxil/ dofetilide/pilsicainide/didanosine/metformin, pts.&lt; 18 yrs.,
   need if ALT/AST return to baseline values & if pt.has no clinic. hep-  mania, delus., neuros., blurr. vis., tinnit., vertigo, palpitat., tachy-  mod.to sev.hepat.impairm.
   atit. signs/other sympt.suggest.of organ dysfunct. Adhere strict.to   card., flush., pancreatit., hepatit., hepat.fail., incr.sweat., alopec.,   Side effects: Lamivudine: Freq: Arthralg., musc. disords., fatig.,
   dos.dur.14 day lead-in period. Dur.1  2 wks ther.critic.to monit.for   eczema, folliculit., skin exfoliat., urticar., arthralg., myalg., impot.,   malaise, fev., headache, insomn., hyperlactataem., N&V, upper
                  st
   sev.& life-threat. skin reacts.& ser.hepatit./hepat.fail. Supplem.ad-  decr./incr. libido, gynaecomast., asthen., malaise, abnorm. coor-  abdom.pain/cramps, diarrh., stomatit., rash, alopec. Less freq:
   dit.200 mg in adult pts.with ren. dysfunct. undergo.haemodialys.  dinat., atax., convuls., migraine headaches, neuralg., paraesthes.,   Anaem., neutropen., thrombocytopaen., lact.acidos., lipodystrophy,
   Adults: Init.200 mg dly.x14 days (i.e. lead-in period) foll.by 200 mg   periph.neuropathy, speech disord., trem., hypoaesthes., amnes.,   pancreatit., elev.in ser. amylase, periph. neuropathy, late onset neu-
   2xdly.in combinat.with at least two antiretrov.agents.to which pt.not   agitat. Freq.not known: GI disords., anorex., gastrit., gastroen-  rologic.disords. in childr.expos.in utero, rhabdomyolys., decr.BMD,
   been prev.expos. Recomm.dos.& monit.to be foll.if concom. anti-  terit., gastro-oesophag.reflux, weight loss, redistribut./accumulat.  osteopen., fract., trans.rise in liv.enz, Freq. unknown: Pure red cell
   retrovir.ther.admin. Tot.dly.dos.not to exceed 400 mg.  of body fat, dyspn., asthma, constip., malabsorpt., nail disord., skin   aplas. Tenofovir disoproxil fumarate: Freq: Abdom.pain, anorex.,
   Paed.pts: 2 mnths.-8 yrs: Recomm.dos: 4 mg/kg 1xdly.for 2 wks.  discolourat., myopath, acne, seborrh. Emtricitabine: Freq: Allerg.  dyspeps., flatul., ren.insuffic./fail., proxim. tubulopathy, proteinur.,
   foll.by 7 mg/kg 2xdly.thereaft. 8 yrs. & old: 4 mg/kg 1xdly for   react., elev.AST/ALT/ hyperbilirubinaem./ creatine kinase, headache,   incr.creatin., ac.tubul. necros., nephrogen.diabet.insipidus, allerg.
   2 wks.foll.by 4 mg/kg 2xdly thereaft. Tot.dly.dos. not to exceed.   dizzin., hyperglycaem., hypertriglyceridem, neutropen, pain, asthen.,   react., incr. amylase, pancreatit., incr.liv.enz., hepatit., dyspn., hy-
   400 mg for any pt.           rash, skin discolourat., sleep disturbs., insomn. Less freq: Anaem.,   pophosphatem., lact.acidos. Dolutegravir: Freq: Headache, diz-
   Adults & Childr.(50 kg or more bm) able to swallow tabs:   angioed., hepatit. Freq.unknown: Lipodystrophy, cushing. appear,   zin., abnorm. dreams, insomn., naus., diarrh., rash, prurit. Less freq:
   Admin.200mg tabs.instead. Oral sol.shake gent.prior to admin., us-  dorso-cervic, fat enlargem.incl. fatal cases,lact.acidos.assoc.with   Hypersens., immune reconstitut.syndr., vomit., flatul., upper abdom.
   ing oral dos.syr. esp.for 5 ml or less/dos.cup which should be rins.   sev.hepatomeg. & steatos. Tenofovir: Freq: Hypophosphataem.,   Pain. Freq.unknown: Abdom.pain/discomf., hepatit.
   with water aft.admin.& rinsing admin.to pt. Recomm. dos.at 200 mg/  anx., insomn., headache, dizzin., incr. transaminas., skin rash.,   Warnings and special precautions: Not indic. for treatm.of
   day (4 mg/kg/day in paed. pts.)for the first 14 days follow.by 200 mg   sweat., asthen. Less freq: Neutropen., hypokalaem., lact.acidos.  chron.hepatit.B infect., safety & effic. not est.in HBV & HIV co-
   2xdly (4 g or 7 mg/kg 2xdly accord.to age for paed.pts) should ther.  infects., monit.hepat. funct. for sev.mnths.in pts.co-infect.with HIV
   interrupt.for more than 7 days.  assoc. with sev.hepatomeg.& steatos., pancreatit., hepat. steatos.,   & HBV who discont.ther.& appropr.init.of anti-hepatit. B ther.poss.
                                hepatit., hepatotox., rais.liv.enzymes, angioed., rhabdomyolys., musc.
   Contraindications: Sev.hepat.dysfunct./underl. liv. disords., Child-  weakn., myalg., osteomalac., myopathy, arthralg., incr. reatinine ,   necess., metabol.abnormalit., eval. for signs of fat redistribut., monit.
   Pugh class B or C, end-stage ren. fail.in pts.not on haemodialys.,   ren. insuffic./fail., proteinur., polyur., ac. tubul. necros., proxim.ren.   fast.ser. lipids & bld.gluc.levs., CV risk assessm.with evid. of lipod-
   pre-treatm./ dur. treatm.values of AST/ALT&gt; 5x ULN until AST/ ALT   tubulopathy, nephrit., nephrogen. diabet.insipid., fev., weight loss.   ystrophy, pts.to seek med.advice if exper. joint pain/aches/stiffn./
   stabilis.&lt; 5x ULN., re-admin.in cases of sev. rash/ rash with con-  Freq. unknown: Lipodystroph., periph.neuropath., GI disords., anx.,   movem.diffic.as osteonecros. poss., opportunist.infects.& other HIV
   stitut. sympts./hypersens. syndr. /if ther.discont.for clinic.hepatit.,   periph.neuropathy, pneum., dyspn., allerg. react.  complicat. may still devel., ARV ther.will not prev. risk of transmiss.
   AST/ALT values &gt; 5x ULN dur.ther.& had rapid recurr.of liv. funct.   Warnings and special precautions: Not indic. for treatm.of   through sex.cont.& bld.contamin. & appropr.precaut.to contin., dis-
   abnormalit.on re-admin., safety in pregn.& lactat. not est., concom.  chron.hepatit.B infect., safety & effic. not est.in HBV & HIV co-  cont.in clinic./lab. find. suggest.lact.acidos./hepatotox., pts.with
   ketoconazole/St.John’s Wort.  infects., monit.hepat. funct. for sev.mnths.in pts.co-infect.with HIV   known risk for liv.dis, pts.with hepatomegaly/ hepatit/ other risk
   Side effects: Rash & sev./life-threat.skin reacts. somet.fatal incl.   & HBV who discont.ther.& appropr.init.of anti-hepatit. B ther.poss.  facts.for liv.dis./hepat.steatos., pts. co-infect.with hepatit.C & treat.
   Stev.-Johns./tox.epiderm. necrolys. /exfol.dermatit., hypersens.  necess., obesity & prolong. nucleoside use poss.risk fact.for lact.  with alpha interferon & ribavarin, eff.on clinic.progress.of HIV-1 not
   syndr., sev.& life threat. hepatotox.incl.fatal fulmin.hepatit.& hepat.   acidos., liv. dis. risk fact., discont.in clinic./lab.find. suggest. lact.   demonst., investig.childr.expos.in utero to nucleoside & nucleotide
   fail., allerg.reacts incl.angioed./anaphylax., ser. -sickn.-like reacts.,   acidos./hepatotox., investig.childr.expos.in utero to nucleoside & nu-  analog.for poss. mitochondr. dysfunct.in case of relev.S&S, dis-
   bld.dyscras., headache, GI disturbs., abnorm.LFT, jaund., myalg., ar-  cleotide analog.for poss. mitochondr. dysfunct.in case of relev.S&S,   cont. ther. until pancreatit.excl.in cases of N&V/abdom. pain/ elev.
   thralg., fatig., fev., constitut.finds.& viscer.involvem., cutan. reacts.  discont. ther. until pancreatit.excl.in cases of N&V/abdom. pain/ elev.  biochem.mark., ren.funct.impairm., safety & effic.not est.in signific.
   (see lit.for detail.descript.& nevirapine re-challenge), ren.dysfunct.,   biochem.mark., safety & effic.not est.in signific. underly. liv. disor-  underly.liv. disords., monit.liv.funct.with pre-exist.liv.dysfunct., cons.
   pancreatit., lipodystrophy, periph.neuropathy.  ds., monit.liv.funct.with pre-exist. liv.dysfunct., cons. ther.interrupt./   ther.interrupt./discont.if evid.of worsen.liv. dis., monit.ren.funct.bef.
   Special precautions: Caref.monit.of pts.with pre-treatm. AST/ALT   discont. if evid.of worsen.liv.dis., ref.to PI of concom. hepat.B or C   init.ther & periodic. thereaft. (4 wkly dur.1st yr.of treatm. & 3 mnthly
   of 2-3x ULN for deteriorat.of liv. funct., adeq.contracept.other than   theraft.), avoid combin.with concurr./recent nephrotox. meds., con-
   hormon.in women of childbear.potent., 1  18 wks.ther.critic. to monit.  meds, monit.liv.enzymes partic. in known/suspect.hepatit.B/C infect.  com.meds.secret.by same ren. pathway, avoid in antiretrov.exper.
                   st
                                hist./ concom.hepatotox meds., eval.risk vs.benef.of cont. ther.if ser.
   for sev.& life-threat.skin reacts.& ser. hepatit./ hepat.fail., great.risk   pts.with HIV-1 harbour.K65R mutat., bone monit.with patholog. bone
                   st
   of hepat.events & skin reacts. occur.1  6 wks.ther., women CD4 +   transaminase.lev.persist.5x&gt;ULN, reg. test.for jaund./bleed tend.,   fract.hist./osteopen.risk, Ca & vit.D supplement. poss.benefic., incr.
                                test for chron. hepatit. B bef.init.ther., sev.ac.exacerbat.of hepatit. B
   &gt;250, men CD4 + &gt; 400 counts incr.risk hepat. adverse events, dos.  risk for sev./fat. hepat. adverse effs.in chron.hepatit.B or C co-infect.,
   esp.14 day lead-in period to be strict.adher.to, dos.escalat.not allow.  aft.discont., immed.risk vs.benefit eval. of cont.ther.when ser.psych.  ref.to PI of concom.hepat.B or C meds., immune reconstit.inflam.
                                sympts.exper., do not admin. in pts. with creatin.clear.&lt; 50 ml/min,
   if rash occur.dur lead-in dos.until rash.resolv., perman. discont.ther.in   syndr., exacerb.of hepatit. dur/ aft.treatm., limit.data in elderly &gt; 65
   pts.exper. sev.rash/rash with constitut. sympts./hypersens.syndr.&   determ. creatin.clear.bef.init./dur.ther., avoid with concom./rec.ne-  yrs., discont. ther.immed.if any hypersens.react.susp./ occurs.& init.
                                phrotox.agents, pts at risk of ren. impairm., monit.ren.funct.& ser.
   viscer. involvem., fail.follow.init.dos.of 200 mg dur.lead-in per.poss.  appropr.ther., avoid in wom.plan. pregn., neur.tube defects in humans
   ser.cutan.react.risk, long delay betw.init. sympts.& medic.cons.may   phosphat.prior to start. treatm.& periodic.dur.ther., antihistam./ cor-  when used at time of concept./early preg., reproduct.toxic. report.,
                                ticoster. for mild to mod.rash to improv.tol.& resolv. rash, discont.in
   incr.risk of more ser. cutan. reacts., women at high.risk than men of   init.pregn.test in women of childbear. potent./periodic.dur.treatm.&
   develp.rash, ther.assoc.rash perform liv.funct.test. immed., perman.  case of sev.skin rash, monit. BMD in pts.with patholog.bone fract.  when pregn. suspect., lamivudine excret.in breast milk, monit. with
                                hist./ at risk of osteopen., Ca & vit.D supplementat.poss benefic.,
   discont.ther.in pts.with mod.to sev. elevat. (AST/ ALT &gt;5 x ULN), incr.  concom.co-trimoxazole, concom.tacrolimus as ren funct poss.affect.,
   AST/ALT lev.and/or chron.hepatit.B&C co-infect.prior to ther. is as-  cholesterol./triglycerid.monit, pts.to seek med. advice if exper.joint   concom.ETR not recomm. unless receiv.concom.ATV + RTV/LPV +
                                pain/aches/stiffn./ movem.diffic.as osteonecros.poss., seiz.hist.,
   soc.with great.risk of hepat.adverse events dur.antiretrovir.ther.in   RTV or DRV + RTV, do not admin.concom.with emtricitabine/ other
   gen., monit.pre-exist. liv.dysfunct.& discont./interr.ther.if worsen.   period. plasma monit.of anticonvuls.ther., eval.for signs of fat re-  cytidine analogues., avoid chron. co-admin.of sorbitol/other osmot.
                                distribut., CV risk assessm.with evid. of lipodystrophy, immune re-
   liv.dis., clinic.chemistry incl.LFT bef.init.ther.& at appropr.interv.dur.,   act.poly-or monosaccharide acohols, admin.2 hrs.bef./6 hrs. aft. poly-
   opportunist.infects.& other HIV infect.complic.poss.contin., alt.ther.to   constit.syndr., opportunist. infects & other HIV complicat.still poss.,   val.cation-cont.antacids, admin.2 hrs.bef./ 6 hrs. aft.Ca/Fe supplem.
   clarithromycin recomm.in Mycobacterium avium-intracellular com-  ther.not proven to prev.HIV transmiss. through sex.cont./bld.contam.,   Interactions: Lamivudine poss.inhib.intracell. phosphorylat. of zal-
                                elderly, pregn.test in women of childbear.age prior to init.ther., barr.
   plex., monit.concom.fluconazole/ warfarin/ methadone maint.pts.  citabine, trimethoprim incr. lamivudine plasma lev., lamivudine incr.
   as narcot.withdr. syndr. report., pts.to report.1 sympts of hepatit.  contracept.tog.with other methods recomm.dur.& for 12 wks.aft.  expos.& peak. plasma lev.of zidovudine, conc.of tenofovir/ concom.
                      st
                                discont.treatm, concom.didanosine/ atazanavir or lopinavir/rito-
   to dr.immed., ther.not a cure, transmiss.reduct.risk of HIV-1 through   med incr.with concom.drugs elimin.by glomerul. & act.tubul.secret.,
   sex.cont./bld.contamin./longt.effs. not known, discont.ther.perm.  navir & discont.if advers. effs.develop, addit.ritonavir.recomm.with   tenofov.ser.conc. incr.by agents decr.ren.funct., C max & AUC of dida-
                                concom. fosamprenavir do not admin. concom. saquinavir as sole
   if mod./sev.LFT abnorm. recur/clinic.hepatit.occur, concom. flu-  nosine incr., atazanavir incr.tenofovir C max/ AUC/C min., lopinavir/
   conazole/ warfarin, consid.decr.concom. rifabutin dos., monit.other   protease inhibit., monit.liv enzym.with concom.meds.assoc.with   ritonavir incr.tenofovir AUC/ C min., indinavir incr.tenofovir C max, teno-
                                hepat. toxic./known or suspect. HVB/C, no dos.recomm. for itra-
   therap.uses requir. concom.hormon.regulat.                 fovir incr. C max of abacavir/indinavir, tenofovir incr.C max/AUC/ Cmin
   Drug interactions: Poss.decr.in plasma conc.of other concom.  conazole avail.theref.seek alt.antifung., rash report. with efavirenz   of atazanavir, poss.incr.metformin/dofetilide/ pilsicainide plasma
                                & clarithromycin theref. consid.alt.eg.azithromycin, combinat.with
   admin.meds.extens. metabol.by CYP3A or CYP2B, saquinavir (hard   conc.with dolutegravir., poss. decr. dolutegravir conc.with oxcar-
   gelatine caps) & indinavir AUC lev.reduc., incr.rifabutin conc.& poss.   other macrolides not stud.  bazepine/ phenytoin/ phenobarb./carbamazepine/St John’s Wort
                                Interactions: Reduc.NNRTI conc.with St John’s Wort expect.,
   high.toxic.risk, fluconazole incr nevirapine expos., warfar.may incr./  though no studies, reduc.dolutegravir plasma conc. with etravirine/
   decr.coagulat.time, AUC, C max & C min signific.low.by rifampicin, elev.  poss.addit.CNS effs.with alcoh. /psychoact.meds., plasma conc.of   efavirenz/nevirapine/ rifampicin, incr.dolutegravir plasma conc.with
                                other compds. that are CYP3A4 substrat.poss.decr., meds.induc. CY-
   trough conc.with CYP isoenzym.inhibits.eg.cimetidine, oestrog. lev.  atazanavir/ atazanavir+ritonavir, decr.dolutegravir conc. with ti-
   of OC’s signific.decr., plasma conc.of methadone decr., decr.NNRTI’s   P3A4 activ.incr.clear., incr.expos.with inhibit.of CYP3A4 or CYP2B6/   pranavir + ritonavir/ritonavir+ fosamprenavir/ darunavir+ritonavir/
                                grapefruit juice, conc.of emtricitabine/tenofovir/concom.med incr.
   conc.& result.sub-optimal lev.with St John’s Wort., ketoconazole &   darunavir+ritonavir+ etravirine, decr.dolutegravir AUC & C max with
   erythromycin signif.inhibit.format.of hydroxylated metabol., poss.  with concom. drugs elim.by glomerul.& act.tubul. secret./ decr.ren.  antacids cont.polyval. cations/ prod.cont.Ca/& Fe.
                                funct, atazanavir conc.decr., atazanavir incr.tenofovir conc., ampre-
   incr.rash risk with prednisone if admin. dur. 1  6 wks.of ther., AUC
                      st
   & C max of ketoconazole signif.reduc.& nevirapine plasma lev. incr.  navir ser. conc. decr., metabol.of indinavir incr., tenofovir conc. incr.  VORIOR 500 mg, (Activo) Hetero [P/S]
                                with lopinavir/ritonavir combinat., lopinavir conc.decr., ritonavir &
                                                              Valaciclovir
   VIRTEM, Emcure, [P/S]        efavirenz conc. incr. with ritonavir, saquinavir conc.decr., didanosine   Indications: Herpes zoster (shingles) reduc.the durat.& proport.of
   Efavirenz 600 mg, emtricitabine 200 mg, tenofovir disoproxil fu-  conc.incr., warfar.plasma conc.incr. /decr., phenytoin/phenobarbit.&   pts.with Zoster assoc.pain, recurr. genit.herpes.in immunocompet.
   marate 300 mg.               efavirenz conc.decr.with these anticonvuls., carbamazepine conc.  adult pts., prevent./ suppress.of recurr.H.simplex infect.of skin &</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page320.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page316.html">316</a>&nbsp;&nbsp;&nbsp;<a href="page317.html">317</a>&nbsp;&nbsp;&nbsp;<a href="page318.html">318</a>&nbsp;&nbsp;&nbsp;<a href="page319.html">319</a>&nbsp;&nbsp;&nbsp;<a href="page320.html">320</a>&nbsp;&nbsp;&nbsp;<a href="page321.html">321</a>&nbsp;&nbsp;&nbsp;<a href="page322.html">322</a>&nbsp;&nbsp;&nbsp;<a href="page323.html">323</a>&nbsp;&nbsp;&nbsp;<a href="page324.html">324</a>&nbsp;&nbsp;&nbsp;<a href="page325.html">325</a>&nbsp;&nbsp;&nbsp;<a href="page326.html">326</a>
             </td>
             <td width="35%"><a href="page322.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page322.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
